G 619

Drug Profile

G 619

Latest Information Update: 08 Aug 1994

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Nonindustrial source
  • Class Antiplatelets
  • Mechanism of Action Platelet aggregation inhibitors; Thromboxane A2 synthase inhibitors; Thromboxane receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Peripheral vascular disorders; Stroke

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top